Annual report pursuant to Section 13 and 15(d)

Note 12 - License Agreement

v3.23.1
Note 12 - License Agreement
12 Months Ended
Dec. 31, 2022
Notes to Financial Statements  
License and Transfer Agreement [Text Block]

12.

License Agreement

 

TUM License

 

The Company and the Technical University of Munich, or TUM, initiated discussions in the second quarter of 2018 to clarify, expand and restructure the research and licensing agreement with TUM, the TUM License, including the parties’ obligations under the TUM License. The TUM License assigns or exclusively licenses to the Company certain intellectual property related to the Company's Anticalin platform technology. The parties' discussions relate to revised commercial terms and to re-initiating additional collaborations between faculty at TUM and Pieris.  While an amended and restated license agreement has not yet been completed, the Company intends to enter into such an amendment. These discussions may also lead to an increase in the Company's collaborative research activities with TUM.